Novartis Snags Japan Approval for CAR-T Therapy Kymriah

Novartis Pharma’s Kymriah (tisagenlecleucel) won approval on March 26 as Japan’s first CAR-T cell therapy. If all goes well, it could be listed for reimbursement as early as May though there are uncertainties surrounding its pricing. With the green light...read more